Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
People using weight management medications return to their pretreatment bodyweight within 2 years of stopping treatment, with reversal of beneficial effects on cardiometabolic markers.
Digital health interventions have gained prominence in the management of chronic diseases, but how do they impact clinical and patient-related outcomes and health behavior in people with type 1 diabetes?
A unusual case of bilateral lower-leg edema that developed in an older woman with SPIDDM shortly after she started basal–bolus insulin therapy with insulin aspart and insulin degludec.
Examine the evidence supporting the expanding role of CGM in type 2 diabetes, from active management of established disease to early identification of dysglycemia in individuals with prediabetes.
Insulin remains key to the management of type 2 diabetes, but its role continues to evolve with the arrival of once-weekly regimens presenting new opportunities and challenges. How can once-weekly insulin therapy be implemented to optimize patient care?
Watch it live: Monday 16 February 2026, 18:00-19:00 (CET)
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
A unusual case of bilateral lower-leg edema that developed in an older woman with SPIDDM shortly after she started basal–bolus insulin therapy with insulin aspart and insulin degludec.
What could be causing involuntary and uncontrolled movements in the right arm and leg of a woman with a 25-year history of diabetes and hypertension, beginning shortly after an intramuscular betamethasone injection for shoulder pain?
A man who achieved diabetes remission after gastric bypass presented with hypoglycemic episodes and endogenous hyperinsulinemia. Hypoglycemia resolved and fasting tests normalized when sacubitril/valsartan was discontinued due to worsening renal function.
In this special edition of Medicine Matters, we're joined by Dr Gregory Lim, Claire Greenhill, and Sarah Onuora, Chief Editors of Nature Reviews Cardiology, Endocrinology, and Rheumatology, for a look back at the advances in their specialties in 2025.
Find out what caught their attention and why, and what they're looking forward to in 2026.
Hypertension is one of the most frequent and consequential comorbidities in people with diabetes, yet its management remains less straightforward than guideline tables might suggest. Epidemiological evidence confirms the high prevalence and the …
Gestational diabetes mellitus (GDM) significantly impacts placental metabolism and microbial composition, leading to transformations at the maternal–fetal interface. In response to hyperglycemia, the placenta undergoes extensive metabolic …
Over the past decade, incretin-based therapies and SGLT2 inhibitors have redefined management of type 2 diabetes (T2D) and obesity. While their glucose-lowering and weight-reducing properties are well established, growing evidence highlights …
Type 2 diabetes mellitus (T2DM) is a leading contributor to the global burden of noncommunicable diseases (NCDs), affecting over 537 million adults worldwide [ 1 ]. Its prevalence is disproportionately high and growing rapidly in low- and …
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
Familiarize yourself with current and emerging ketone monitoring systems and the most useful clinical scenarios in which to use them through our podcasts and e-learning modules. Lower the barriers to effective prevention of diabetic ketoacidosis.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills with real cases, vodcasts, and interactive infographics.
Type 2 diabetes is a major global health concern. The International Diabetes Federation estimated that 589 million adults (ages 20–79 years) worldwide were living with diabetes, and of these, approximately 90% had type 2 diabetes [ 1 ]. In the USA …
Glycoprotein 130 (gp130) is a signal-transducing receptor widely expressed across tissues and serves as a key mediator for the interleukin-6 (IL-6) family of cytokines, including IL-6, IL-11, Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic …
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic β-cells, leading to lifelong insulin dependence and persistent hyperglycaemia, which causes numerous micro and macrovascular …
The global prevalence of diabetes mellitus (DM) continues to grow [ 1 ] and diabetic eye disease is increasingly becoming a public health concern as a major cause of visual impairment and blindness among the working-age population [ 2 ]. Diabetic …
People using weight management medications return to their pretreatment bodyweight within 2 years of stopping treatment, with reversal of beneficial effects on cardiometabolic markers.
Digital health interventions have gained prominence in the management of chronic diseases, but how do they impact clinical and patient-related outcomes and health behavior in people with type 1 diabetes?
People who achieve prediabetes remission during a lifestyle intervention may halve their long-term risk for cardiovascular death or hospitalization for heart failure.
Medication non-adherence remains a significant challenge in the management of type 2 diabetes. How should it be assessed, what are the consequences, and what are the interventions designed to improve adherence?